bioMérieux will be awarded up to EUR54.5 million by France's Agence de l'Innovation Industrielle for molecular biology research
bioMérieux announced that it will be awarded up to EUR54.5 million over the next ten years by France's Agence de l'Innovation Industrielle to help fund the "Advanced Diagnostics and New therapeutic Approaches" (ADNA) program, led by Mérieux Alliance. Of this amount, EUR25.6 million will be in the form of grants and EUR28.9 million in the form of loans. The financing is subject to approval by the European Union, which is expected to make a decision in the second quarter of 2007.
The ADNA program aims to develop personalized medical solutions for cancer, infectious diseases and rare genetic diseases. Four strategically aligned partners, bioMérieux, Généthon, GenoSafe® and Transgene, have teamed up to meet the challenge. An initial partnership between bioMérieux and Ipsen in oncology research has given the project an additional boost.
Over the next ten years, the assistance provided by the agency will help finance programs designed to:
* Find, identify and validate biomarkers. The identification of biomarkers shall help scientists to develop diagnostic tests for earlier disease detection, determine appropriate treatments and monitor treatment response in patients.
* Develop new molecular diagnostic platforms to perform high-value-added analyses of infectious diseases and certain types of cancer.
Other news from the department business & finance
